Bionomics Ltd Share Price (NASDAQ: BNOX)

Last updated on December 23, 2024 at 12:00 am IST

$₹

This instrument is not available for trading on the INDmoney app on 23 Dec 2024

Check the interactive Bionomics Ltd Stock chart to analyse performance

Bionomics Ltd Key Stats

Check Bionomics Ltd key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.0
Open	$0.251
Market Capitalization	$5.0M
Today's Volume	$7.0M
Revenue TTM	$662.0K
EBITDA	$-17.4M
Earnings Per Share (EPS)	$-14.32
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-78.44%

Global Institutional Holdings in Bionomics Ltd

Name
Holdings %
Name
Holdings %

Analyst Recommendation on Bionomics Ltd Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Bionomics Ltd(by analysts ranked 0 to 5 stars)

Bionomics Ltd Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$3.6M	↓ 41.21%
Net Income	$-5.1M	↓ 60.66%
Net Profit Margin	-141.25%	↑ 69.88%

	FY20	Y/Y Change
Revenue	$1.4M	↓ 60.06%
Net Income	$-2.8M	↓ 45.01%
Net Profit Margin	-194.47%	↓ 53.22%

	FY21	Y/Y Change
Revenue	$531.5K	↓ 66.3%
Net Income	$-5.0M	↑ 62.39%
Net Profit Margin	-937.11%	↓ 742.64%

	FY22	Y/Y Change
Revenue	$2.9M	↑ 500.75%
Net Income	$-10.6M	↑ 130.36%
Net Profit Margin	-359.34%	↑ 577.77%

	FY23	Y/Y Change
Revenue	$290.7K	↓ 89.65%
Net Income	$-14.2M	↑ 41.19%
Net Profit Margin	-4.9K%	↓ 4543.17%

	FY24	Y/Y Change
Revenue	$20.0K	↓ 95.38%
Net Income	$-15.5B	↑ 72936.61%
Net Profit Margin	-77.5M%	↓ 7.745592749E7%

Q1 FY23

Q2 FY23

Q3 FY23

Q4 FY23

Q3 FY24

	Q1 FY23	Q/Q Change
Revenue	$172.6K	↑ 185.87%
Net Income	$-5.2M	↓ 29.13%
Net Profit Margin	-3.0K%	↑ 9180.4%

	Q2 FY23	Q/Q Change
Revenue	$31.3K	↓ 81.94%
Net Income	$-3.3M	↓ 36.83%
Net Profit Margin	-10.6K%	↓ 7561.32%

	Q3 FY23	Q/Q Change
Revenue	$172.8K	↑ 270.27%
Net Income	$-5.2M	↑ 5.83%
Net Profit Margin	-3.0K%	↑ 7561.31%

	Q4 FY23	Q/Q Change
Revenue	$98.9K	↓ 42.73%
Net Income	$-10.5M	↑ 100.37%
Net Profit Margin	-10.6K%	↓ 7561.33%

	Q3 FY24	Q/Q Change
Revenue	$98.9K	-
Net Income	$-804.8K	↑ 888.46%
Net Profit Margin	-813.44%	-

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-2.3M	↓ 66.18%

	FY20	Y/Y Change
Profit	$-1.3M	↓ 41.51%

	FY21	Y/Y Change
Profit	$-2.8M	↑ 85.24%

	FY22	Y/Y Change
Profit	$-4.8M	↑ 89.39%

	FY23	Y/Y Change
Profit	$-8.5M	↑ 83.98%

	FY24	Y/Y Change
Profit	$-434.4K	↓ 96.56%

Q1 FY23

Q2 FY23

Q3 FY23

Q4 FY23

Q2 FY24

Q3 FY24

	Q1 FY23	Q/Q Change
Profit	$-2.8M	↓ 42.39%

	Q2 FY23	Q/Q Change
Profit	$-1.6M	↓ 41.51%

	Q3 FY23	Q/Q Change
Profit	$-2.8M	↑ 14.3%

	Q4 FY23	Q/Q Change
Profit	$-5.2M	↑ 85.51%

	Q2 FY24	Q/Q Change
Profit	$-436.3K	↓ 91.56%

	Q3 FY24	Q/Q Change
Profit	$-5.2M	↑ 1084.7%

FY19

FY20

FY21

FY22

FY23

	FY19	Y/Y Change
Operating Cash Flow	$-7.6M	↓ 27.74%
Investing Cash Flow	$137.3K	↑ 143.28%
Financing Cash Flow	$2.1M	↑ 56.71%

	FY20	Y/Y Change
Operating Cash Flow	$-2.7M	↓ 64.32%
Investing Cash Flow	$-134.6K	↓ 198.72%
Financing Cash Flow	$-3.7M	↓ 275.33%

	FY21	Y/Y Change
Operating Cash Flow	$-5.8M	↑ 93.14%
Investing Cash Flow	$-61.3K	↓ 58.9%
Financing Cash Flow	$24.1M	↓ 689.02%

	FY22	Y/Y Change
Operating Cash Flow	$-10.6M	↑ 99.24%
Investing Cash Flow	$437.0K	↓ 875.13%
Financing Cash Flow	$13.1M	↓ 40.93%

	FY23	Y/Y Change
Operating Cash Flow	$-9.5M	↓ 5.36%
Investing Cash Flow	$322.1K	↓ 22.87%
Financing Cash Flow	$2.5M	↓ 80.14%

Q1 FY23

Q2 FY23

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-435.5K	↓ 89.37%
Investing Cash Flow	$96.3K	↑ 50.93%
Financing Cash Flow	$-204.4K	↓ 107.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-3.1M	↑ 605.27%
Investing Cash Flow	$96.9K	↑ 0.0%
Financing Cash Flow	$2.4M	↓ 1263.52%

About Bionomics Ltd

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Organization	Bionomics Ltd
Employees	8
CEO	Dr. Spyridon Papapetropoulos M.D., Ph.D.
Industry	Miscellaneous

Key Management of Bionomics Ltd

Name	Title
Dr. Spyridon Papapetropoulos M.D., Ph.D.	CEO, President & Director
Mr. Timothy M. Cunningham CPA, M.B.A.	Chief Financial Officer
Ms. Elizabeth Doolin	Senior Vice President of Clinical Development
Dr. Julie Kerner Ph.D.	Senior Vice President of Business Operations
Dr. Mark A. Smith M.D., Ph.D.	Chief Medical Officer
Mr. Adrian Hinton BEC, F.C.A.	Financial Controller

Important FAQs about investing in BNOX Stock from India :

What is Bionomics Ltd share price today?

Bionomics Ltd share price today is as on December 23, 2024 at 12:00 am IST at the close of the market. Bionomics Ltd share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Bionomics Ltd share?

Bionomics Ltd share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Bionomics Ltd stock price today i.e. December 23, 2024 at 12:00 am IST is closed at , lower by 100% versus the 52 week high.

How to invest in Bionomics Ltd Stock (BNOX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bionomics Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bionomics Ltd Shares .

What is the minimum amount required to buy Bionomics Ltd Stock (BNOX) from India?

Indian investors can start investing in Bionomics Ltd (BNOX) shares with as little as ₹92.706 or $1 (as of April 05, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹927.06 in Bionomics Ltd stock (as per the Rupee-Dollar exchange rate as on April 05, 2026). Learn more about fractional shares .

What are the returns that Bionomics Ltd has given to Indian investors in the last 5 years?

Bionomics Ltd stock has given 0.0% share price returns and 26.44% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Aebi Schmidt Holding Ag
$9.59
+2.24%
Oppenheimer Holdings-cl A
$91.08
+1.66%
F&g Annuities & Life Inc
$26.05
+1.01%
Bitwise Coin Income Strat
$11.11
+0.45%
Jianzhi Education Technology Group Company Ltd.
$0.85
+2.41%
Wisdomtree Us Quality Dividend Gr Etf
$88.07
-0.02%
Ft Vest Laddered Nasdaq Buffer Etf
$35.55
+0.14%
Luda Technology Group Ltd
$4.36
+35.4%
Franklin Templeton Etf Tr Multisector Incm
$25.45
+0.12%

Explore all